Afshan Malik, MD

Myeloma Specialist, NYC. Managing Editor @MMTrials

[Afshan Malik, MD @afshanmalikmd]

Multiple Myeloma Education Platform for Myeloma Community #MYELOMA #mmsm https://t.co/r1RZvUyQ05

[National Comprehensive Cancer Network (NCCN) @NCCN]

Join us for the evening events at the NCCN Hematologic Malignancies Congress, featuring a session on Myelodysplastic Syndromes, a welcome reception, and a chance to explore the exhibit hall. Tune in now: https://t.co/68MoZOWKON #NCCNhem24

[National Comprehensive Cancer Network (NCCN) @NCCN]

Welcome to day 1 of the Hematologic Malignancies Congress! Join us for afternoon educational sessions focusing on AML and ALL, visit the exhibit hall, and more.
Tune in now: https://t.co/68MoZOWKON #NCCNhem24

[Stomping Ground Sports @TheStompingGrnd]

We are officially on BRACKET WATCH!

Anybody who joined our SGS Bracket Challenge we are witnessing history!

And if you didn’t there’s still time to follow along!

Brackets like this don’t come around often!

This is AMERICAS BRACKET!

Name: zara
Rank: 115 out of 22,000,000

[Gurbakhash Kaur @GKaurMD]

Finally, my favorite topic is discussed at @Myeloma_Society - @US_FDA
IMS-FDA meting - the exclusion of Oligo/Non secretory disease and plasma cell leukemia in #mmsm clinical trials. I hope this leads to a change.

[Afshan Malik, MD @afshanmalikmd]

Different Season, Different Stadium, Same Result
https://t.co/rSs5uQNbpl
@TheStompingGrnd @BuffaloBills #KCvsBUF #BuffaloBills #KansasCityChiefs #BillsMafia @billsupdates @TheBillsWire @BuffaloBillsPR #NFL #Bills @BuffaloWoody @OCHBuffalo

[Surbhi Sidana, MD @SurbhiSidanaMD]

#ASH22 #WomenInHeme

[Ben Derman @bdermanmd]

BMS-986354 presented beautifully by @End_myeloma - A BCMA-directed CAR T cell therapy designed to shorten manufacturing time and enhance durability of response through selection of specific T cell phenotypes. Implications for further CAR t-cell development! #ash22

[Noopur Raje @NoopurRajeMD]

Blenrep withdrawal unfortunate and premature specifically when we have 2 ongoing phase 3 trials… agree that DREAMM-3 was not the best trial design and did not meet statistical endpoints…but did not do harm and did benefit #mmsm patients

[Vincent Rajkumar @VincentRK]

Re Belantamab withdrawal from market. @GSKUS #Myeloma

An unfortunate casualty of:

1) Wrong dose and schedule
2) Wrong trial design for phase III — going against an active control is high risk.
3) Wrong price at launch — drained support from MDs

[. @IreneGhobrial]

WoMMen in smoldering myeloma

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

This morning on @GMA, Dr. Sergio Giralt reunited with @RobinRoberts to discuss the latest advances in bone marrow transplants in the last 10 years. If you'd like to support this lifesaving research, click here: https://t.co/evAS3CVFUH

[Robin Roberts @RobinRoberts]

I'm amazed and grateful for all the advancements in bone marrow transplants that the medical community has made in the past 10 years since I had my transplant. Coming up next on @GMA...my doctors Dr. Sergio Giralt and Dr. Gail Roboz join us LIVE...(1/2)

[Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 @Rfonsi1]

CIRCULATING PLASMA CELLS (cPCs) IN MYELOMA (MM)

Several studies have recently reported on the prognostic significance of cPCs in patients with MM. The study of cPCs is of high relevance, but not new. For curation purposes only, I want to cite older studies
#mmsm
1/x

[Myeloma Clinical Trials @MMTrials]

SCIP & SAVOR FOR A CURE - A Fundraising Hosted By: Fatima and Jimmy Scipione - Sat Oct 15th, 2022 #mmsm #MultipleMyeloma @IMFmyeloma
https://t.co/WuxOAQfoJq
Please Donate:
https://t.co/Vb227FwIbw

[Erinn Goldman @DrErinnGoldman]

I'm thrilled to host a discussion with leading hematologist @jmikhaelmd in the upcoming #MultipleMyeloma (MM) live event on #TwitterSpaces on behalf of @Pfizer. Join us on Tuesday, 10/4 at 7 pm EST to discuss unmet needs and emerging innovations in MM: https://t.co/HfBRMpgpbg

[Saad Z. Usmani MD MBA FASCO 🇺🇸🇵🇰 @szusmani]

As expected, the @MSKCancerCenter #woMMen triumphed over DFCI, kudos to @MalinHultcrantz @CarlynRTanMD for wonderful presentations!! #mmsm

[Myeloma Clinical Trials @MMTrials]

NCT04555551:Phase 1 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for Multiple Myeloma - Just Published in NEJM #mmsm #MultipleMyeloma #cart #Immunotherapy #curemyeloma @ESmithMDPhD @MSKCancerCenter
https://t.co/mhPxuwAlD2

[Eric Smith @ESmithMDPhD]

Our report of first-in-human GPRC5D-targeted CAR T cells for MM is out in NEJM! The trial was led by Sham Mailankody and could not be done without the amazing clinical, correlative science, stats, & cell manufacturing teams.
Happy to share our bench>bedside journey
1/10

[Radhika Bansal (She/Her) @Radhika_Bansl]

@MayoCancerCare @heMEGirl_MD @FStPierreMD going strong @SocietyofHemOnc #SOHO22 @MayoHemeOnc @MayoMrfa @WomenInLymphoma @NUHemOncFellow

Stop by level 2 for a quick peep 👀 in the #CART #Research 🌎 #lymsm #bmt #MedTwitter

[Myeloma Clinical Trials @MMTrials]

Soho 2022 - 10th annual hybrid meeting #soho22 #mmsm #MultipleMyeloma